Stay updated on Pembrolizumab in Recurrent PCNSL Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent PCNSL Clinical Trial page
- Check6 days agoChange DetectedNew entries identify the investigator and sponsoring institution (Prof. Dr. Matthias Preusser; Medical University of Vienna) and add user-focused navigation items (How to Read a Study Record, Common Questions, How to Join a Study). Additionally, the page labels are updated (Intervention/Treatment) and a new revision tag (Revision: v3.6.0) is introduced.SummaryDifference2%

- Check13 days agoChange DetectedThe page now shows revision v3.5.5, replacing the previous v3.5.4. This update reflects a new page/template version rather than changes to substantive content.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.5.4 replaces the prior v3.5.3, signaling a small metadata update. This change does not modify any study details, eligibility criteria, or results on the page.SummaryDifference0.1%

- Check56 days agoChange DetectedThe page’s displayed revision/version number was updated from v3.5.2 to v3.5.3, reflecting a website release rather than a change to the underlying study information.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.1%

- Check92 days agoChange DetectedAdded revision note: v3.5.0. Removed revision note: v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Recurrent PCNSL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.